<DOC>
	<DOCNO>NCT00705250</DOCNO>
	<brief_summary>The standard treatment patient HL respond treatment come back treatment stem cell transplant . When patient eligible transplant HL come back transplant , standard treatment option . These patient receive chemotherapy participate clinical trial . Bendamustine HCl chemotherapy agent effective treating patient various disease , include non-Hodgkin 's lymphoma , multiple myeloma , breast cancer . It recently approve treatment chronic lymphocytic leukemia . In addition , small study Eastern Europe show bendamustine HCl likely effective treat HL . This study find effect bendamustine HCl transplant-ineligible patient HL respond come back treatment .</brief_summary>
	<brief_title>Bendamustine HCL Relapsed Primary Refractory Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Histologic diagnosis Classical Hodgkin lymphoma , confirm department hematopathology MSKCC . Patients relapse autologous stem cell transplant must biopsy transplant confirm relapse Hodgkin 's disease . Patients relapse allogeneic transplant must also biopsy posttransplant . Age &gt; = 18 All patient must PET avid measurable disease . Last chemotherapy &gt; = 4 week start Bendamustine HCl Receiving treatment HL Patients must normal baseline cardiac function base upon echocardiogram gate blood pool scan ( MUGA ) ejection fraction &gt; = 50 % Patients must serum creatinine &lt; = 1.5 mg/dl ; creatinine &gt; 1.5 mg/dl creatinine clearance must &gt; 60 ml/minute . Patients must ANC &gt; 1000/mcl Platelets &gt; 100,000/mcl . Patients must bilirubin level &lt; 2.0 mg/dl absence history Gilbert 's disease ( pattern consistent Gilbert 's ) . Patients must Hepatitis B surface antigen Hepatitis B core antibody negative Hepatitis C negative . Patients must fail autologous stem cell transplant ineligible autologous stem cell transplant due chemorefractory disease ( define &lt; 50 % response standard salvage chemotherapy ) . Women premenopausal must negative pregnancy test Subjects must agree use appropriate contraception 4 week completion chemotherapy . Patients must HIV negative . If patient history malignancy cutaneous basal cell squamous cell carcinoma , must diseasefree â‰¥ 5 year time enrollment . Patients guardian must capable provide informed consent . Patients either parenchymal brain leptomeningeal involvement . 7 consecutive day prednisone therapy prior therapy . Known pregnancy breastfeeding . Medical illness unrelated HL , opinion attend physician principal investigator preclude administration chemotherapy safely . This include patient uncontrolled infection , chronic renal insufficiency , myocardial infarction within past 6 month , unstable angina , cardiac arrhythmia chronic atrial fibrillation chronic active persistent hepatitis History malignancy diseasefree interval &lt; 5 year , exclude curatively treat cutaneous basal cell squamous cell carcinoma carcinoma insitu cervix . Relapse &lt; 6 month post allogeneic stem cell transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Bendamustine HCL</keyword>
</DOC>